NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT05065411,Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT05065411,VERU-024,TERMINATED,"STAGE 1: To determine the safety of enobosarm 9 milligram (mg) once daily (QD) used in combination with a CDK 4/6 inhibitor \[Verzenio® (abemaciclib) tablets, for oral use, 150 mg twice daily (BID)\].

STAGE 2: To demonstrate the efficacy and safety of enobosarm 9 mg QD in combination with abemaciclib 150 mg BID (Enobosarm Combination Group) versus Estrogen Blocking Agent (Control Treatment Group) in the treatment of estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), androgen receptor positive (AR+) with a AR% nuclei staining ≥40% metastatic breast cancer that have previously experienced disease progression on an estrogen blocking agent plus (palbociclib) as measured by progression free survival (PFS) according to RECIST 1.1 criteria.",NO,Metastatic Breast Cancer,"DRUG: Enobosarm & Abemaciclib Combo|DRUG: non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant","Primary endpoint for the study is the median progression free survival (PFS) in the Enobosarm Combination Group compared to the Control Treatment Group in patients with AR% nuclei staining ≥40%. Progression will be defined based on RECIST 1.1 criteria, STAGE 1: To determine the safety of enobosarm 9 mg once daily (QD) used in combination with abemaciclib tablets, for oral use, 150 mg twice daily (BID)\].

STAGE 2: To demonstrate the efficacy of enobosarm in combination with abemaciclib (Enobosarm Combination Group) versus an estrogen blocking agent, (non-steroidal AI, steroidal AI (exemestane with or without everolimus) or fulvestrant Control Treatment Group) in the treatment of AR+ER+HER2 (AR% nuclei staining ≥40%) metastatic breast cancer as measured by PFS according to RECIST 1.1., Day 1 to Day 300","Objective Response Rate (ORR), proportion of subjects with a best tumor response of ORR (partial response [PR] or complete response [CR]) on study, Objective Response Rate (ORR), proportion of subjects with a best tumor response of ORR (partial response \[PR\] or complete response \[CR\]) on study, Day 1 to Day 300",,Veru Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,5,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,V2000701,2022-04-11,2023-10-19,2024-01-09,2021-10-04,,2024-02-26,"Ironwood Cancer & Research Centers, Chandler, Arizona, 85224, United States|Banner MDACC, Gilbert, Arizona, 85234, United States|Arizona Oncology Associates, PC-HOPE, Tucson, Arizona, 85711, United States|Los Angeles Cancer Network One Oncology, Los Angeles, California, 90017, United States|UCLA Parkside Cancer Center, Los Angeles, California, 90095, United States|Sharp Center for Research, San Diego, California, 92123, United States|Sansum Clinic, CA, Santa Barbara, California, 93105, United States|Innovative Clinical Research Institute, Whittier, California, 90603, United States|Med OncologyHematology Consultants, PA Newark, Newark, Delaware, 19713-7007, United States|Lakes Research, Miami Lakes, Florida, 33014, United States|Maryland Oncology Hematology, P.A., Annapolis, Maryland, 21401, United States|Baystate Regional Cancer Program - D'Amour Center for Cancer Care, Springfield, Massachusetts, 01199-1005, United States|University of Mississippi Medical Center, Jackson, Mississippi, 39213, United States|Washington University St. Louis, Saint Louis, Missouri, 63110, United States|Renown Health, Reno, Nevada, 89502, United States|Summit Medical Group, Florham Park Campus, Florham Park, New Jersey, 07932-1049, United States|The New York Hospital, Westbury, New York, 11590, United States|The Lindner Center for Research and Education at the Christ Hospital, Cincinnati, Ohio, 45219, United States|Toledo Clinic Cancer Centers - Main Office, Toledo, Ohio, 43623, United States|UPMC Magee-Women's Hospital, Pittsburgh, Pennsylvania, 15219, United States|Texas Oncology, PA, Dallas, Texas, 75246, United States|Texas Oncology, PA, Denton, Texas, 76201, United States|Texas Oncology, P.A., El Paso, Texas, 79902, United States|Texas Oncology, P.A., Flower Mound, Texas, 75028, United States|UT MD Anderson CC, Houston, Texas, 77030, United States|Texas Oncology, P.A., San Antonio, Texas, 78240, United States|Texas Oncology, P.A., Tyler, Texas, 75702, United States|Virginia Oncology Assoc, Norfolk, Virginia, 23502, United States|University of Washington Seattle Cancer Center Alliance (SCCA), Seattle, Washington, 98109-1023, United States|Cancer Care Northwest, Spokane, Washington, 99216, United States",
